CombiGene has become the owner of more than 90 percent of the shares in Panion. CombiGene has requested initiation of compulsory acquisition proceeding to acquire all remaining shares and warrants in Panion and will promote a delisting of Panion’s shares and warrants from Spotlight.
Panion Animal Health AB (publ) (”Panion”) has previously announced that CombiGene AB (publ) (”CombiGene”) holds more than 90 percent of the outstanding shares in Panion.
Through CombiGene’s public offer as of 18 April 2019, the issue of new shares that Panion completed to CombiGene on 30 August 2019 and through the purchase of shares on the market, CombiGene now holds 91.42 percent of the outstanding shares in Panion. Furthermore, CombiGene holds 84.91 percent of Panion’s warrants of series TO1 (”Warrants”).
CombiGene has requested initiation of compulsory acquisition proceeding to acquire all remaining shares and Warrants in Panion in accordance with the Companies Act (2005:551). In connection to this, CombiGene intends to, as specified in the press release regarding the public offer, promote a delisting of Panion’s shares and Warrants from Spotlight Stock Market.
For further information, please contact:
Jan Nilsson (CEO)
Telephone: +46704663163
E-mail: jan.nilsson@combigene.com
Arne Ferstad (Chairman of the Board)
Telephone: +447496526142
E-mail: arne.ferstad@ankor-consultants.com
The information was submitted for publication, through the agency of Jan Nilsson, on 13 September 2019, 08.15 CEST.